Onglyza Lawsuit Lawyers

A review by the FDA in April 2015 highlighted that AstraZeneca's diabetes drug, Onglyza, may significantly increase the risk of all-cause mortality. Despite generating substantial sales, concerns arose from the SAVOR study, which linked Onglyza to a 27% increased risk of heart failure hospitalization. The FDA delayed a combination drug launch involving Onglyza, seeking more data. Legal actions are underway for adverse reactions, including death. The FDA's advisory meeting could lead to a Black Box warning, potentially impacting Onglyza's sales.

Onglyza May Increase Death Rate

AstraZeneca Diabetes Drug Death Rate

 

AstraZeneca Diabetes Drug Increase Risk Of Death. A review published by the U.S. Food and Drug Administration (FDA) on April 10, 2015 indicates that Astra Zeneca’s key diabetes drugs-Onglyza (saxagliptin)-may be tied to “a significantly increased risk of all-cause mortality.”

Onglyza is a key AstraZeneca diabetes product that, in 2014, brought the drug maker sales of $820 million. AstraZeneca purchased the full rights to Onglyza in 2013 from a diabetes partnership it previously created with Bristol-Myers Squibb, according to Biopharmadive.com.

Our firm is pursuing class action lawsuits on behalf of individuals, or their loved ones, who suffered serious adverse reactions, including death, following treatment with Onglyza.

FDA Delays Onglyza Drug Combo

In October 2015, the FDA delayed AstraZeneca’s launch of a combination diabetes drug containing Onglyza and Farxiga (dapagliflozin). The agency indicated that it required more clinical trial data for the new combination drug.

Studies have suggested that Onglyza increases the risk of cardiac death. Farxiga is a SGLT-2, a class of drugs that has been under scrutiny for diabetic ketoacidosis, stroke, and cardiac problems.

AstraZeneca received a Complete Response Letter from the FDA asking for more detailed research and information. The company predicted in 2014 that the new combination drug could garner peak annual sales of $3 billion. In the first half of 2015, Onglyza sales generated $391 million and Farxiga reached $205 million.

Research Points to Potential Onglyza Cardiac Death

A prior study, entitled SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus), of more than 16,000 patients taking the blood sugar medication, Onglyza, revealed that they experienced a 27 percent increased risk of hospitalization due to heart failure when compared to the control group. An analysis conducted by the FDA revealed that the heart failure risk is valid, according to Reuters.

Although the overall trial results did not reveal a higher risk of death, a more in-depth analysis of the research involving only those patients who took Onglyza suggests “a significantly increased risk of all-cause mortality,” the review found.

While the FDA indicated that the causes of death were, in some cases, “multifactorial” and some study participants may have been diagnosed with serious medical conditions before their death, the FDA also noted that, it “is not reassured” by the increased risk, “and we do not necessarily view this pattern of variable causes as evidence the mortality signal is due to chance,” according to Reuters.

Prior Agency Calls for Increased Research of Diabetes Medications

The FDA issued guidance in December 2008 that mandated drug manufacturers to conduct research that show that emerging diabetes drugs do not increase cardiovascular risks. The agency’s guidance followed mounting concerns regarding a number of diabetes medications.

FDA Convenes Meeting to Discuss Onglyza Risks

The FDA is convening an advisory committee the week of April 13, 2015 to discuss the implications revealed by the SAVOR study along with risks associated with, Nesina, a diabetes drug manufactured by Takeda Pharmaceutical Co. Onglyza received FDA approval in 2009; Nesina received FDA approval in 2013.

Should the meeting lead to a Black Box warning-the FDA’s most stringent warning-Onglyza sales may experience a significant dip in profits, Biopharmadive noted.

A Leerink analyst stated that the agency’s worries regarding all-cause mortality came as a surprise, Reuters wrote, and may lead to a reduction of up to 50 percent in the $1.8 billion Onglyza peak annual sales estimate, should competing drug, Januvia, not reveal similar issues.

Need Legal Help Regarding
AstraZeneca Diabetes Drug?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).
Free Consultation
Parker Waichman LLP
Are you inquiring about a new matter?
Please Describe the Details of Your Inquiry
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
4.8 from 549 Reviews

Client Reviews

Our law firm is ready to represent you in your injury case. We’ve helped many New York residents as well as those needing help nationwide. Contact our team for a free case consultation today.

Paralegal Tina assisted me in securing a settlement from VCF World Trade Center. Her performance was totally professional and thorough I would recommend her service to anyone.
reginald peavy
a year ago
Gina Viti was our paralegal during the claim process and was very responsive, professional and supportive. We appreciate all she did to bring the claim to a satisfactory conclusion. Positive Responsiveness, Professionalism
ann gallas
3 years ago
There was never a doubt that I would get what we asked for Alex Kathleen and biker were spot on and always helpful and available and a minute notice I highly recommend them
David Silverman
3 months ago
I would like it known, to those concerned, what a wonderful job Benita Rollis did on my behalf concerning the 9/11 Victims Compensation Fund claim. Her skill and compassion made my experience with Parker Waichman one that I will not soon forget. From the very beginning, Benita approached this whole process with the knowledge and logic of a true professional and someone who clearly loves what she does. Every time the VCF threw me a curve ball during this process, Benita knew exactly how to handle it, alleviating all fears. Also, the fact that she made herself so accessible was a major comfort. Parker Waichman is a better law firm because of Benita Rollis. I will most definitely recommend her to all who may be in need of your service. Thank you Benita and thank you Parker Waichman for helping me realize justice and absolutely changing my life as well as restoring my faith in the legal system!
Marc Abramson
5 years ago

Contact Us Today

If you or a loved one has been injured in an accident or have been injured by another party in some other way, we are here to stand up for your rights. Our personal injury attorneys have been representing injury victims and their families in Long Island and throughout the nation since the early 1980s.